FATE logo

Fate Therapeutics, Inc.

FATE
Healthcare|Biotechnology|US
$1.83
-0.01 (-0.81%)
Tangible Book / Share
$1.08
Cash / Share
$1.13
Next Earnings Report
Feb 25, 2027
EPS est. -$0.29 · Revenue est. $1.1M
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Nov 5, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (6)

Sep 2027
Est. completion
P1Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT06308978n=244
Jan 2028
Est. completion
P1Non-Small Cell Lung Cancer
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105n=119
Jun 2028
Est. completion
P1Astrocytoma
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
NCT07560865n=9
Oct 2028
Est. completion
P1P2ANCA-Associated Vasculitis (AAV)
FT839 in Autoimmune Diseases
NCT07800871n=446
May 2029
Est. completion
P1Advanced Solid Tumor
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
NCT06241456n=351
Jul 2029
Est. completion
P2Lupus Nephritis
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
NCT07570862n=53

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Dec 2025
Novel Neuroradiological Workflow for the Assisted DIAgnosis and Management of DEMentia with Artificial Intelligence
NCT06877182
Jun 2025
P1
FT819 in Subjects With B-cell Malignancies
NCT04629729

Recent Press Releases

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Nov 5, 2026 · GlobeNewsWire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2026 · GlobeNewsWire
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Oct 26, 2026 · GlobeNewsWire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026 · GlobeNewsWire
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
Oct 1, 2026 · GlobeNewsWire
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
Sep 25, 2026 · GlobeNewsWire
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
Sep 16, 2026 · GlobeNewsWire
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
Sep 9, 2026 · GlobeNewsWire
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
Sep 3, 2026 · GlobeNewsWire
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Aug 14, 2026 · GlobeNewsWire

SEC Filings (52)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 2026S-3Shelf registrationDocumentIndex
Nov 5, 2026424B5Offering prospectusDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Nov 5, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Sep 28, 20268-KMaterial eventDocumentIndex
Aug 13, 2026S-8Employee stock planDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Jul 8, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 15, 20268-KMaterial eventDocumentIndex
Jun 4, 20268-KMaterial eventDocumentIndex
May 13, 202610-QQuarterly reportDocumentIndex
May 13, 20268-KMaterial eventDocumentIndex
Apr 24, 2026ARSAnnual report to holdersDocumentIndex
Apr 24, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 24, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 22, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 26, 202610-KAnnual reportDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Nov 13, 202510-QQuarterly reportDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex
Oct 27, 20258-KMaterial eventDocumentIndex
Oct 20, 2025S-8Employee stock planDocumentIndex
Oct 14, 20258-KMaterial eventDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 12, 202510-QQuarterly reportDocumentIndex
Aug 12, 20258-KMaterial eventDocumentIndex
Jul 29, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jul 3, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Jun 17, 20258-K/AMaterial eventDocumentIndex
Jun 4, 2025S-8Employee stock planDocumentIndex
May 30, 20258-KMaterial eventDocumentIndex
May 15, 2025SC 13GPassive 5%+ stakeDocumentIndex
May 13, 202510-QQuarterly reportDocumentIndex
May 13, 20258-KMaterial eventDocumentIndex
May 9, 2025SC 13GPassive 5%+ stakeDocumentIndex
Apr 23, 2025SC 13G/APassive 5%+ stakeDocumentIndex